圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688289 圣湘生物

已收盘 05-10 15:00:00

{"stockData":{"symbol":"688289","market":"SH","secType":"STK","nameCN":"圣湘生物","latestPrice":20.6,"timestamp":1715324400000,"preClose":20.81,"halted":0,"volume":3759985,"delay":0,"floatShares":588000000,"shares":588000000,"eps":0.6538,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.21,"latestTime":"05-10 15:00:00","open":20.95,"high":21,"low":20.44,"amount":77666500,"amplitude":0.0269,"askPrice":20.61,"askSize":168,"bidPrice":20.6,"bidSize":226,"shortable":0,"etf":0,"ttmEps":0.6538,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715563800000},"adr":0,"adjPreClose":20.81,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715304600000,1715311800000],[1715317200000,1715324400000]],"highLimit":22.89,"lowLimit":18.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":588459803,"pbRate":1.66,"roa":"--","roe":"1.12%","epsLYR":0.62,"committee":-0.311891,"marketValue":12122000000,"floatMarketCap":12122000000,"peRate":31.508106,"changeRate":-0.0101,"turnoverRate":0.0064,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-13。","afterMarket":{"amount":0,"volume":0,"close":20.6,"buyVolume":0,"sellVolume":2658,"time":1715326439505,"indexStatus":"已收盘 05-10 15:30:00","preClose":20.81}},"requestUrl":"/m/hq/s/688289","defaultTab":"news","newsList":[{"id":"2434090293","title":"圣湘生物获国投证券买入评级，6个月目标价为24.78元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434090293","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434090293?lang=zh_cn&edition=full","pubTime":"2024-05-09 21:14","pubTimestamp":1715260460,"startTime":"0","endTime":"0","summary":"5月9日，圣湘生物获国投证券买入评级，近一个月圣湘生物获得3份研报关注。研报预计公司2024-2026年营业收入分别同比增长51.5%、31.6%、26.0%；归母净利润分别同比增长0.2%、34.5%、30.4%，成长性突出；首次给予买入-A的投资评级，6个月目标价24.78元，相当于2024年40倍的动态市盈率。研报认为，圣湘生物在呼吸道病原体检测领域的产品布局十分全面，能够为医院提供从门诊部到住院部、从单检到多联检的全套产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405092114238aed0300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405092114238aed0300&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434056920","title":"圣湘生物拟与关联方共同投资合资公司 聚焦快速药敏检测领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2434056920","media":"新京报","top":-1,"share":"https://www.laohu8.com/m/news/2434056920?lang=zh_cn&edition=full","pubTime":"2024-05-09 14:02","pubTimestamp":1715234570,"startTime":"0","endTime":"0","summary":"新京报讯 5月9日，圣湘生物发布公告，拟与关联方湖南湘江圣湘生物产业基金合伙企业共同投资合资公司湖南圣微速敏生物科技有限公司。圣湘生物拟与产业基金共同投资湖南圣微速敏，合计投资金额为人民币5333万元。本次交易后，圣湘生物将持有湖南圣微速敏39.9985%股份，产业基金将持有湖南圣微速敏60.0015%股份。同时，圣湘生物拟将参股公司First Light 21.69%的股权全部转让至湖南圣微速敏下属全资子公司，转让对价为221.58万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914035487e34504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914035487e34504&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434611086","title":"AI制药新进展：谷歌推出新一代模型 产业链一览","url":"https://stock-news.laohu8.com/highlight/detail?id=2434611086","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2434611086?lang=zh_cn&edition=full","pubTime":"2024-05-09 08:14","pubTimestamp":1715213647,"startTime":"0","endTime":"0","summary":"美东时间周三，谷歌DeepMind发布了新一代预测蛋白质结构的AlphaFold 3模型，能够帮助科学家更精确地针对疾病机制，从而开发出更有效的治疗药物。据太平洋证券医药，AI制药内涵丰富，主要包括：数字生物学、计算机药物发现、实验室自动化、AI 辅助临床试验等。整体而言AI技术在制药领域的应用价值主要体现在缩短试验周期、节省成本、促进新事物发现、提升试验成功概率等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509075702861ebda0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509075702861ebda0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433723910","title":"圣湘生物(688289.SH)拟携产业基金新设合资公司 聚焦快速药敏检测领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2433723910","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433723910?lang=zh_cn&edition=full","pubTime":"2024-05-08 20:32","pubTimestamp":1715171573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣湘生物 公告，公司拟与关联方湖南湘江圣湘生物产业基金合伙企业共同投资合资公司湖南圣微速敏生物科技有限公司，其中公司投资金额为人民币5333万元。同时，公司拟将参股公司First Light Diagnostics, Inc.21.69%的股权转让至合资公司下属全资子公司，转让对价为221.58万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118970.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433672172","title":"圣湘生物(688289.SH)：投资5333万设立合资公司，聚焦快速药敏检测领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2433672172","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2433672172?lang=zh_cn&edition=full","pubTime":"2024-05-08 20:00","pubTimestamp":1715169645,"startTime":"0","endTime":"0","summary":"快讯正文【圣湘生物携手关联方投资5,333万元设立合资公司】5月8日，圣湘生物宣布与湖南湘江圣湘生物产业基金合伙企业合作，共同投资设立湖南圣微速敏生物科技有限公司，投资总额为人民币5,333万元。合资公司将购入FirstLightDiagnostics,Inc.股权圣湘生物还计划将持有的FirstLightDiagnostics,Inc.21.69%股权转让给合资公司下属全资子公司，转让金额为2,215,835美元。合资公司未来聚焦快速药敏检测合资公司将作为整体运营主体，集中资源，致力于打造快速药敏检测领域的研发、应用开发及商业转化。下载和讯APP查看快讯，体验更佳>>","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082128518ae8db94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082128518ae8db94&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433174756","title":"圣湘生物(688289.SH)：拟与关联方投资湖南圣微速敏并转让参股公司FirstLight股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2433174756","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2433174756?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:41","pubTimestamp":1715168460,"startTime":"0","endTime":"0","summary":"格隆汇5月8日丨圣湘生物公布，拟与关联方湖南湘江圣湘生物产业基金合伙企业共同投资合资公司湖南圣微速敏生物科技有限公司，其中，公司合计投资金额为人民币5,333万元。后续将依托合资公司作为整体运营，进一步聚焦于快速药敏检测领域，加速促进产业研究、应用开发及商业转化。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-08/doc-inaupqtm0607185.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-08/doc-inaupqtm0607185.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433735069","title":"圣湘生物获得发明专利授权：“检测肾上腺高血压的基因检测panel及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2433735069","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433735069?lang=zh_cn&edition=full","pubTime":"2024-05-08 02:11","pubTimestamp":1715105473,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示圣湘生物新获得一项发明专利授权，专利名为“检测肾上腺高血压的基因检测panel及其用途”，专利申请号为CN202210101156.3，授权日为2024年5月7日。进一步地，本发明提供了一种肾上腺高血压的基因检测panel，包括该基因检测panel的试剂和装置，以及该基因检测panel的用途。今年以来圣湘生物新获得专利授权16个，较去年同期增加了45.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800002129.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432130016","title":"圣湘生物获得发明专利授权：“核酸检测装置及核酸检测方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432130016","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2432130016?lang=zh_cn&edition=full","pubTime":"2024-05-01 02:40","pubTimestamp":1714502436,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示圣湘生物新获得一项发明专利授权，专利名为“核酸检测装置及核酸检测方法”，专利申请号为CN202110890821.7，授权日为2024年4月30日。上述核酸检测装置，降低了外界因素对检测结果的干扰，显著缩小了核酸检测的操作环境限制，降低了对操作人员的要求。今年以来圣湘生物新获得专利授权13个，较去年同期增加了18.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050100003095.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431397088","title":"圣湘生物AB面：“二次创业”稍现亮点，新冠退潮后“继任”仍难产丨钛媒体深度","url":"https://stock-news.laohu8.com/highlight/detail?id=2431397088","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2431397088?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:36","pubTimestamp":1714469765,"startTime":"0","endTime":"0","summary":"立于当下时间节点，资本市场眼中的圣湘生物也呈现出了两面性，一方面，疫情管控放开后公司提出“二次创业”口号，并已现亮点，只是含金量有待商榷，另一方面，新冠核酸检测突然退潮后，能够完全接替的支柱型业务尚未诞生。2023年Q1的低基数，源于圣湘生物与新冠核酸检测业务的“断崖式分手”。交易完成后圣湘生物将成为科华生物的第一大股东，这引发行业轰动。6月，圣湘生物披露了第二起收购，无业绩对赌、溢","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043017363987c33ec2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043017363987c33ec2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431399882","title":"圣湘生物将于5月17日召开股东大会，审议2024年度董事薪酬方案等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2431399882","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431399882?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:56","pubTimestamp":1714467418,"startTime":"0","endTime":"0","summary":"金融界4月30日消息，圣湘生物发布公告，将于2024年5月17日召开年度股东大会，网络投票同日进行。股权登记日为5月13日，当日收市后持有圣湘生物股票的投资者可以参与投票。会议地点：上海市闵行区华西路680号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301658158b658e7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301658158b658e7d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431517802","title":"北向资金4月29日净买入圣湘生物80.39万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431517802","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431517802?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:30","pubTimestamp":1714440635,"startTime":"0","endTime":"0","summary":"4月29日, 北向资金增持圣湘生物80.39万股，连续3日增持。截止当日收盘，沪股通共持有圣湘生物1036.31万股，占流通股1.76%。沪股通增持金额前五个股分别为江苏银行、陕西煤业、宇通客车、三一重工、韦尔股份。圣湘生物近5个交易日上涨9.98%，沪股通累计增持196.02万股；近20个交易日上涨5.55%，沪股通累计增持324.99万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300937388b642b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300937388b642b35&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431804992","title":"圣湘生物(688289)呼吸道产品需求提升，2023年常规试剂收入翻倍增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2431804992","media":"信达证券","top":-1,"share":"https://www.laohu8.com/m/news/2431804992?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:19","pubTimestamp":1714439960,"startTime":"0","endTime":"0","summary":"2023年受国内外公共卫生防控政策变化影响，新冠核酸检测试剂及仪器需求下降，公司实现营收10.07亿元，而常规试剂业务表现亮眼，实现收入7.83亿元。2024年一季度公司实现营业收入3.91亿元，我们认为跟流感高发，呼吸道检测产品需求持续有关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009295387c18a0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009295387c18a0d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431805240","title":"圣湘生物：管理层表示2024年预期销售费用率控制在32%左右 管理费用率下降至12%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2431805240","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431805240?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:33","pubTimestamp":1714437183,"startTime":"0","endTime":"0","summary":"来源：Gangtise投研【圣湘生物】管理层表示，2023年因加大市场投入导致了较高的费用率，销售费用率达35%，管理费用率达18%，研发费用率达19%。2024年将加强运营管理，提升人均效能，预期销售费用率控制在32%左右，管理费用率下降至12%左右，研发费用率下降至13%左右。根据公司模型测算，当营收达到30亿元规模时，销售净利率能够达到30%左右，当营收达到40亿元规模时，销售净利率能够达到35~40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300833078b63fca8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300833078b63fca8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431418854","title":"圣湘生物获信达证券买入评级，呼吸道产品需求提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2431418854","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431418854?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:44","pubTimestamp":1714394678,"startTime":"0","endTime":"0","summary":"4月29日，圣湘生物获信达证券买入评级，近一个月圣湘生物获得1份研报关注。研报认为，公司的常规试剂业务在2023年实现翻倍以上增长，尤其是呼吸道产品需求的提升。公司打造了矩阵式的呼吸道疾病领域产品布局，与美团、京东合作，提供快速的居家核酸检测服务。此外，通过技术创新、战略合作投资及产业链整合，圣湘生物在分子诊断、免疫和POCT等领域形成了多元化的业务布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042920444087bf6652&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042920444087bf6652&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431568885","title":"圣湘生物涨5.72%，华鑫证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431568885","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431568885?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:32","pubTimestamp":1714379521,"startTime":"0","endTime":"0","summary":"今日圣湘生物涨5.72%，收盘报20.16元。2024年3月4日，华鑫证券研究员胡博新发布了对圣湘生物的研报《公司事件点评报告：四季度呼吸道检测产品快速增长》，该研报对圣湘生物给出“买入”评级。研报中预测公司2023-2025年收入分别为10.06、14.71、18.38亿元，归母净利润分别为3.60、3.08、4.11亿元，EPS分别为0.61、0.52、0.70元，当前股价对应PE分别为35.3、41.2、30.9倍，我们认为呼吸道检测业务可为公司带来长期业绩增长弹性，首次覆盖，给予“买入”投资评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291638008b61126a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291638008b61126a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431212170","title":"圣湘生物创1月新高 营收同比增加100.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431212170","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2431212170?lang=zh_cn&edition=full","pubTime":"2024-04-29 11:00","pubTimestamp":1714359605,"startTime":"0","endTime":"0","summary":"北向资金方面，圣湘生物04月26日获得北向资金增持29.12万股，截至04月26日，北向资金当前共持有圣湘生物955.91万股，市值1.92亿元，持股占流通股比为1.62%。最新财报显示，今年一季报，圣湘生物实现营业收入3.91亿元，同比增长100.31%，净利润为8,102.47万元，同比增长35.01%，基本每股收益为0.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291130327924ae70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291130327924ae70&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430709741","title":"圣湘生物2023年营收10.07亿净利3.64亿 董事长戴立忠薪酬70.06万","url":"https://stock-news.laohu8.com/highlight/detail?id=2430709741","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2430709741?lang=zh_cn&edition=full","pubTime":"2024-04-28 10:51","pubTimestamp":1714272706,"startTime":"0","endTime":"0","summary":"挖贝网4月28日，圣湘生物 近日发布2023年年度报告，报告期内公司实现营业收入1,007,118,933.74元，同比下滑84.39%；归属于上市公司股东的净利润363,721,131.71元，同比下滑81.22%。公司2023年度营业收入及净利润等指标同比下降超过50%，与行业整体情况一致，主要系国内外公共卫生防控政策变化，导致新冠核酸检测试剂及仪器需求急剧下降，相关业务收入下降所致。公告显示，报告期内董事、监事、高级管理人员报酬合计1,973.95万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042810535087b930f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042810535087b930f7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430379765","title":"圣湘生物(688289)3月31日股东户数2.05万户，较上期减少6.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430379765","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430379765?lang=zh_cn&edition=full","pubTime":"2024-04-27 17:10","pubTimestamp":1714209035,"startTime":"0","endTime":"0","summary":"证券之星消息，近日圣湘生物披露，截至2024年3月31日公司股东户数为2.05万户，较12月31日减少1472.0户，减幅为6.7%。在医疗器械行业个股中，圣湘生物股东户数低于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.09万户。从股价来看，2023年12月31日至2024年3月31日，圣湘生物区间跌幅为1.28%，在此期间股东户数减少1472.0户，减幅为6.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700024831.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-28","address":"湖南省长沙市岳麓区高新技术产业开发区麓松路680号","stockEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":0.1105},{"period":"3month","weight":0.0153},{"period":"6month","weight":0.2031},{"period":"1year","weight":0.1745},{"period":"ytd","weight":0.0537}],"companyName":"圣湘生物科技股份有限公司","boardCode":"AI0027","perCapita":"28730股","boardName":"医药制造业","registeredCapital":"58845万元","compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.042},{"period":"3month","weight":0.1007},{"period":"6month","weight":0.038},{"period":"1year","weight":-0.0468},{"period":"ytd","weight":0.0604}],"survey":"　　圣湘生物科技股份有限公司的主营业务为以自主创新基因技术为核心，集诊断试剂和仪器的研发、生产、销售，以及第三方医学检验服务于一体的体外诊断整体解决方案，其主要产品为病毒性肝炎系列产品、生殖道感染与遗传系列产品、儿科感染系列产品、呼吸道感染系列产品、核酸血液筛查系列产品、科研、公共卫生、动物疫病系列产品、核酸提取系列产品、生化系列产品、全自动核酸检测反应体系构建系列产品、POCT移动分子诊断系统系列产品、荧光PCR检测分析软件、第三方医学检验服务、科研服务。","serverTime":1715507221439,"listedPrice":50.48,"stockholders":"20482人(较上一季度减少6.70%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣湘生物,688289,圣湘生物股票,圣湘生物股票老虎,圣湘生物股票老虎国际,圣湘生物行情,圣湘生物股票行情,圣湘生物股价,圣湘生物股市,圣湘生物股票价格,圣湘生物股票交易,圣湘生物股票购买,圣湘生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}